Education
About Us
Working with TipRanks
Follow Us
TOT BIOPHARM International Co. Ltd. (HK:1875)
:1875
RESEARCH TOOLSreports
1875 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$0.70 - HK$2.53
Previous CloseN/A
Volume400.00
Average Volume (3M)145.20K
Market Cap
HK$1.55B
Enterprise ValueHK$1.23B
Total Cash (Recent Filing)HK$381.26M
Total Debt (Recent Filing)¥395.47M
Price to Earnings (P/E)37.7
Beta0.52
Next Earnings
Aug 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding772,787,900
10 Day Avg. Volume117,200
30 Day Avg. Volume145,200
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-7.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$2.40Price Target Upside20.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
TOT BIOPHARM International Co. Ltd. News
PremiumCompany Announcements
TOT BIOPHARM Passes Key Resolutions at AGM
PremiumCompany Announcements
TOT BIOPHARM Announces 2025 AGM Details and Key Resolutions
PremiumCompany Announcements
TOT BIOPHARM Proposes Name Change to BioDlink InternationalPremiumCompany Announcements
TOT BIOPHARM Announces Board Committee Changes for Compliance
PremiumCompany Announcements
TOT BIOPHARM Announces Board and Committee Restructuring
PremiumCompany Announcements
TOT BIOPHARM Announces Board Changes with New Director Appointments
PremiumCompany Announcements
TOT BIOPHARM Announces New Board and Committee Structure1875 FAQ
What was TOT BIOPHARM International Co. Ltd.’s price range in the past 12 months?
TOT BIOPHARM International Co. Ltd. lowest stock price was HK$0.70 and its highest was HK$2.53 in the past 12 months.
What is TOT BIOPHARM International Co. Ltd.’s market cap?
TOT BIOPHARM International Co. Ltd.’s market cap is HK$1.55B.
When is TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date?
TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date is Aug 08, 2025 which is in 48 days.
How were TOT BIOPHARM International Co. Ltd.’s earnings last quarter?
TOT BIOPHARM International Co. Ltd. released its earnings results on Mar 11, 2025. The company reported HK$0.004 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.004.
Is TOT BIOPHARM International Co. Ltd. overvalued?
According to Wall Street analysts TOT BIOPHARM International Co. Ltd.’s price is currently Undervalued.
Does TOT BIOPHARM International Co. Ltd. pay dividends?
TOT BIOPHARM International Co. Ltd. does not currently pay dividends.
What is TOT BIOPHARM International Co. Ltd.’s EPS estimate?
TOT BIOPHARM International Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TOT BIOPHARM International Co. Ltd. have?
TOT BIOPHARM International Co. Ltd. has 772,787,900 shares outstanding.
What happened to TOT BIOPHARM International Co. Ltd.’s price movement after its last earnings report?
TOT BIOPHARM International Co. Ltd. reported an EPS of HK$0.004 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.942%.
Which hedge fund is a major shareholder of TOT BIOPHARM International Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1875
TOT BIOPHARM International Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.48%
12-Months-Change
Fundamentals
Return on Equity
4.92%
Trailing 12-Months
Asset Growth
2.26%
Trailing 12-Months
Company Description
TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of oncology drugs. The company is focused on providing innovative therapies and solutions for cancer treatment, leveraging its capabilities in biologics and small molecule drugs. TOT BIOPHARM operates in the pharmaceutical sector, with a commitment to improving quality of life for cancer patients through its cutting-edge research and development efforts.
Technical Analysis
3SBio
―
Sino Biopharmaceutical
―
Coolpad Group
―
Wuxi Biologics (Cayman)
―
CSPC Pharmaceutical Group
―